These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10895875)

  • 1. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.
    Wasada T; Kawahara R; Iwamoto Y
    Diabetes Care; 2000 Jul; 23(7):1039-40. PubMed ID: 10895875
    [No Abstract]   [Full Text] [Related]  

  • 2. Are the results really different?
    Reaven GM
    Diabetes Care; 2000 Jul; 23(7):1040. PubMed ID: 10895876
    [No Abstract]   [Full Text] [Related]  

  • 3. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
    Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
    Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor.
    Framnes-DeBoer SN; Bakke E; Yalamanchili S; Peterson H; Sandoval DA; Seeley RJ; Arble DM
    Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E62-E71. PubMed ID: 31794265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus.
    Cincotta AH; Schiller BC; Meier AH
    Metabolism; 1991 Jun; 40(6):639-44. PubMed ID: 1865827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
    Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
    Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity.
    Duman BS; Turkoglu C; Gunay D; Cagatay P; Demiroglu C; Buyukdevrim AS
    Diabetes Nutr Metab; 2003 Aug; 16(4):243-50. PubMed ID: 14768774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat.
    Hamann A; Benecke H; Le Marchand-Brustel Y; Susulic VS; Lowell BB; Flier JS
    Diabetes; 1995 Nov; 44(11):1266-73. PubMed ID: 7589822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM.
    Ludvik B; Nolan JJ; Baloga J; Sacks D; Olefsky J
    Diabetes; 1995 Sep; 44(9):1121-5. PubMed ID: 7657038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint.
    Ribeiro-de-Oliveira A; Guerra RM; Fóscolo RB; Marubayashi U; Reis AM; Coimbra CC
    Pharmacol Biochem Behav; 2001 Feb; 68(2):229-33. PubMed ID: 11267627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
    Kamath V; Jones CN; Yip JC; Varasteh BB; Cincotta AH; Reaven GM; Chen YD
    Diabetes Care; 1997 Nov; 20(11):1697-701. PubMed ID: 9353611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes.
    Meneilly GS; Elliott T
    Diabetes Care; 1999 Jan; 22(1):112-8. PubMed ID: 10333911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus.
    Scobie IN; Kesson CM; Ratcliffe JG; Maccuish AC
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):179-85. PubMed ID: 6342861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
    Maccario M; Grottoli S; Procopio M; Oleandri SE; Barberis A; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1996 Apr; 19(4):219-23. PubMed ID: 8862501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
    Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
    J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
    Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for non-insulin-dependent diabetes mellitus.
    Haffner SM
    J Hypertens Suppl; 1995 Aug; 13(2):S73-6. PubMed ID: 8576792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terguride attenuates prolactin levels and ameliorates insulin sensitivity and insulin binding in obese spontaneously hypertensive rats.
    Golda V; Ficková M; Pinterova L; Jurcovicová J; Macho L; Zórad S
    Physiol Res; 2001; 50(2):175-82. PubMed ID: 11522045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.